Skip to content

Study · Animal study (in vivo) · rat · 1996

6 results

Sequential effects of chronic human PTH (1-84) treatment of estrogen-deficiency osteopenia in the rat.

Mitlak BH, Burdette-Miller P, Schoenfeld D, Neer RM

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Apr 1996Cited by 31 (Europe PMC)

PMID8992873 (opens in a new tab)DOI10.1002/jbmr.5650110403 (opens in a new tab)PepBankPUB-08992873
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with estrogen-deficiency bone loss, the highest human PTH 1‑84 doses increased spinal, femoral, and total skeletal mass above normal.

    In plain wordsIn rats with estrogen-deficiency bone loss, the highest human PTH doses increased skeletal mass above normal levels.

    Peptide
    PTH 1-84 (parathyroid hormone)
    Outcome
    IncreaseSkeletal mass
    Study

    ratn: not reported in source

    estrogen-deficiency osteopenia
    Comparator
    Normal levels
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The highest doses of PTH increased spinal, femoral, and total skeletal mass to supra-normal levels and stimulated cortical endosteal bone formation.
    1 context sentence
    Summary · context
    To explore the reasons for this important difference, we evaluated the dose- and time-dependence of human PTH 1-84 treatment effects on bone mass and biochemical markers of bone metabolism in rats with estrogen-deficiency bone loss.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with estrogen-deficiency bone loss, the highest human PTH 1‑84 doses stimulated cortical endosteal bone formation.

    In plain wordsIn rats with estrogen-deficiency bone loss, the highest human PTH doses stimulated bone formation at the inner cortical surface.

    Peptide
    PTH 1-84 (parathyroid hormone)
    Outcome
    IncreaseCortical endosteal bone formation
    Study

    ratn: not reported in source

    estrogen-deficiency osteopenia
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The highest doses of PTH increased spinal, femoral, and total skeletal mass to supra-normal levels and stimulated cortical endosteal bone formation.
    1 context sentence
    Summary · context
    To explore the reasons for this important difference, we evaluated the dose- and time-dependence of human PTH 1-84 treatment effects on bone mass and biochemical markers of bone metabolism in rats with estrogen-deficiency bone loss.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats, spine and whole-skeleton mass and density increased with human PTH 1‑84, but the increase slowed during continued highest-dose treatment (p < 0.01).

    In plain wordsIn rats, spine and whole-skeleton mass and density increased with human PTH, but the increase slowed during continued highest-dose treatment.

    Peptide
    PTH 1-84 (parathyroid hormone)
    Outcome
    IncreaseSpine and whole-skeleton mass and density trajectory
    Study

    ratn: not reported in source

    estrogen-deficiency osteopenia
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Spine and whole skeleton mass and density increased rapidly at first, but then increased more slowly; the rate of change decreased significantly (p < 0.01) during continued treatment with the highest doses of PTH.
    1 context sentence
    Summary · context
    To explore the reasons for this important difference, we evaluated the dose- and time-dependence of human PTH 1-84 treatment effects on bone mass and biochemical markers of bone metabolism in rats with estrogen-deficiency bone loss.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats, the highest human PTH 1‑84 doses increased serum osteocalcin (p < 0.001), followed by an early plateau and return toward baseline.

    In plain wordsIn rats, serum osteocalcin increased with the highest human PTH doses, then plateaued and returned toward baseline.

    Peptide
    PTH 1-84 (parathyroid hormone)
    Outcome
    MixedSerum osteocalcin
    Study

    ratn: not reported in source

    estrogen-deficiency osteopenia
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Serum osteocalcin, a marker of osteoblast function, increased with the highest doses of PTH (p < 0.001), but reached an early plateau and later returned toward baseline.
    1 context sentence
    Summary · context
    To explore the reasons for this important difference, we evaluated the dose- and time-dependence of human PTH 1-84 treatment effects on bone mass and biochemical markers of bone metabolism in rats with estrogen-deficiency bone loss.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats, human PTH 1‑84 increased urinary pyridinoline excretion throughout treatment in a time-dependent manner (p < 0.001).

    In plain wordsIn rats, urinary pyridinoline excretion increased throughout human PTH treatment.

    Peptide
    PTH 1-84 (parathyroid hormone)
    Outcome
    IncreaseUrinary pyridinoline excretion
    Study

    ratn: not reported in source

    estrogen-deficiency osteopenia
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Urinary excretion of pyridinolines, a marker of osteoclast function, increased in a time-dependent fashion throughout treatment (p < 0.001).
    1 context sentence
    Summary · context
    To explore the reasons for this important difference, we evaluated the dose- and time-dependence of human PTH 1-84 treatment effects on bone mass and biochemical markers of bone metabolism in rats with estrogen-deficiency bone loss.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In rats, human PTH 1‑84 increased serum 1,25(OH)2 vitamin D dose dependently, followed by a decrease toward control levels despite continued treatment.

    In plain wordsIn rats, human PTH increased serum active vitamin D, which then decreased toward control levels despite continued treatment.

    Peptide
    PTH 1-84 (parathyroid hormone)
    Outcome
    MixedSerum 1,25(OH)2 vitamin D
    Study

    ratn: not reported in source

    estrogen-deficiency osteopenia
    Outcome group
    Bone and joint · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Serum 1,25(OH)2 vitamin D levels increased in a dose-related fashion, but then decreased toward control levels despite continued treatment.
    1 context sentence
    Summary · context
    To explore the reasons for this important difference, we evaluated the dose- and time-dependence of human PTH 1-84 treatment effects on bone mass and biochemical markers of bone metabolism in rats with estrogen-deficiency bone loss.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.